A Phase 3 interventional study of Brentuximab vedotin and Rituximab in Diffuse Large B-cell Lymphoma, sponsored by Seagen, a wholly owned subsidiary of Pfizer. Active, not recruiting at 143 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-21.
Sponsored by Seagen, a wholly owned subsidiary of Pfizer (part of Pfizer) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies in Lymphoma, Large B-Cell, Diffuse by Pfizer — none open to participants now, 1 under way, 1 of them phase 3. Lymphoma, Large B-Cell, Diffuse · Pfizer.
Among the 25 studies in Lymphoma, Large B-Cell, Diffuse by Pfizer, this one is the 2nd largest by enrollment, is one of 2 that started in 2020, is one of 3 in phase 3, and was the 20th registered.
1,872 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.
Browse Lymphoma, Large B-Cell, Diffuse studies →None of the 25 studies in Lymphoma, Large B-Cell, Diffuse by Pfizer is open now. The open studies under Lymphoma, Large B-Cell, Diffuse, anywhere →
Of the 266 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 177 (67%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 11 · Phase 3 3
First in 2006; this study’s year is marked. 2 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 240 is above the median of 44 across 1,501 interventional studies indexed under Lymphoma, Large B-Cell, Diffuse.
Median enrollment 58 across the 25 interventional studies. Of the 23 that completed or were terminated, 10 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Seagen, a wholly owned subsidiary of Pfizer, one of the names counted as Pfizer. Under that name alone:
Seagen, a wholly owned subsidiary of Pfizer is the lead sponsor of 30 studies on the registry; 4 are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 3 (27%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 25 studies in Lymphoma, Large B-Cell, Diffuse by Pfizer, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Participants in this study will have diffuse large B-cell lymphoma (DLBCL) that has come back or not gotten better with treatment. The trial will study whether brentuximab vedotin plus two drugs works better to treat this type of cancer than the two drugs alone.
Participants will be randomly assigned to get either brentuximab vedotin or placebo. The placebo will look like brentuximab vedotin, but has no medicine in it. Since the study is "blinded," participants and their doctors will not know whether a participant gets brentuximab vedotin or placebo. All participants in the study will get rituximab and lenalidomide. These are drugs that can be used to treat DLBCL.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants must have R/R disease following 2 or more lines of prior systemic therapy.
Participants must be or CAR-T ineligible according to the investigator and must meet at least one of the following criteria:
Exclusion Criteria:
Previous treatment with brentuximab vedotin or lenalidomide.
Current therapy with medications (including ), other systemic anti-neoplastic, or agents
a) Prednisone (or equivalent) ≤10 mg/day may be used for non-lymphomatous purposes
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brentuximab vedotin + lenalidomide + rituximab
Drug: Brentuximab vedotin · Drug: Rituximab · Drug: Lenalidomide
Placebo + lenalidomide + rituximab
Drug: Rituximab · Drug: Lenalidomide · Other: Placebo
1.2 mg/kg administered into the vein (IV; intravenously) infusion every 3 weeks
375 mg/m\^2 administered via intravenous infusion on Cycle 1 Day 1. 1400 mg injected under the skin (subcutaneous) permitted every 3 weeks from Cycle 2 Day 1 through end of treatment.
20 mg given by mouth (orally) daily
Administered via intravenous infusion every 3 weeks
Overall Survival (OS)
OS was defined as the time from the date of randomization to the date of death due to any cause. Participants who had not died were censored at the last known alive date or the data cutoff date, whichever was earlier. OS was estimated using the Kaplan-Meier method.
Time frame: From the date of randomization until date of death or censoring date, whichever occurred first (maximum up to 50 months)
Progression-Free Survival (PFS) as Assessed by Investigator Per Lugano 2014
PFS was defined as the time from the date of randomization to the date of first documentation of progressive disease (PD) or to death due to any cause, whichever occurred first, based on the investigator assessment of tumor response according to the criteria defined by the Lugano Classification, 2014.
Time frame: From date of randomization until the first documentation of PD or to death due to any cause, whichever occurred first (maximum up to 50 months)
Objective Response Rate (ORR) as Assessed by Investigator Per Lugano 2014
ORR per Lugano 2014 by investigator was defined as the percentage of participants with a response assessment of complete response (CR) or partial response (PR) per the Lugano 2014 response criteria as assessed by the investigator.
Time frame: From the date of randomization until PD or initiation of new anticancer therapy (maximum up to 50 months)
Complete Response (CR) Rate as Assessed by Investigator Per Lugano 2014
CR rate per Lugano 2014 by investigator was defined as the percentage of participants with a best response of CR per the Lugano 2014 response criteria as assessed by the investigator.
Time frame: From the date of randomization until PD or initiation of new anticancer therapy (maximum up to 50 months)
Duration of Response (DOR) as Assessed by Investigator Per Lugano 2014
DOR was defined as the time from the first documentation of objective tumor response (CR or PR) to the first documentation of tumor progression per the Lugano 2014 response criteria, as assessed by the investigator, or death due to any cause, whichever occurred first.
Time frame: From the date of first documented response of CR or PR to the first documented PD or death from any cause, whichever occurred first (maximum up to 50 months)
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
An adverse event (AE) was any untoward medical occurrence in a clinical investigational participant administered a medicinal product and which did not necessarily have a causal relationship with this treatment. TEAEs were defined as events that were new or worsened on or after receiving the first dose of study treatment and up through 30 days after the last dose of brentuximab vedotin or lenalidomide or 110 days after last dose of rituximab, whichever was later. AEs included both serious AE (SAEs) and all other AEs. An AE was classified as an SAE if it met one of the following criteria: fatal, life threatening, required or prolonged hospitalization, disabling/ incapacitating, congenital anomaly or birth defect, medically significant.
Time frame: From first dose of study treatment (Day 1) up to 30 days after last dose of brentuximab vedotin or lenalidomide or 110 days after last dose of rituximab, whichever was later (maximum up to 50 months)
Number of Participants With TEAEs Based on Maximum Severity
An AE was any untoward medical occurrence in a clinical investigational participant administered a medicinal product and which did not necessarily have a causal relationship with this treatment. TEAEs were defined as events that were new or worsened on or after receiving the first dose of study treatment and up through 30 days after the last dose of brentuximab vedotin or lenalidomide or 110 days after last dose of rituximab, whichever was later. AE severity graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version (v) 5.0 where, grade 1=mild AE; grade 2=moderate AE; grade 3=severe AE; grade 4= life-threatening; urgent intervention indicated; and grade 5= death related to AE.
Time frame: From first dose of study treatment (Day 1) up to 30 days after last dose of brentuximab vedotin or lenalidomide or 110 days after last dose of rituximab, whichever was later (maximum up to 50 months)
Number of Participants With Treatment Emergent Serious Adverse Events (TESAEs)
TEAEs were defined as events that were new or worsened on or after receiving the first dose of study treatment and up through 30 days after the last dose of brentuximab vedotin or lenalidomide or 110 days after last dose of rituximab, whichever was later. An AE was classified as an SAE if it met one of the following criteria: fatal, life threatening, required or prolonged hospitalization, disabling/ incapacitating, congenital anomaly or birth defect, medically significant.
Time frame: From first dose of study treatment (Day 1) up to 30 days after last dose of brentuximab vedotin or lenalidomide or 110 days after last dose of rituximab, whichever was later (maximum up to 50 months)
Number of Participants With TEAEs: Through Study Completion Date
An AE was any untoward medical occurrence in a clinical investigational participant administered a medicinal product and which did not necessarily had a causal relationship with this treatment. TEAEs were defined as events that were new or worsened on or after receiving the first dose of study treatment and up through 30 days after the last dose of brentuximab vedotin or lenalidomide or 110 days after last dose of rituximab, whichever was later. AEs included both SAEs and all other AEs.
Time frame: From first dose of study treatment (Day 1) through study completion
Number of Participants With TEAEs Based on Maximum Severity: Through Study Completion Date
An AE was any untoward medical occurrence in a clinical investigational participant administered a medicinal product and which did not necessarily had a causal relationship with this treatment. TEAEs were defined as events that were new or worsened on or after receiving the first dose of study treatment and up through 30 days after the last dose of brentuximab vedotin or lenalidomide or 110 days after last dose of rituximab, whichever was later. AE severity graded using the NCI-CTCAE v 5.0 where, grade 1=mild AE; grade 2=moderate AE; grade 3=severe AE; grade 4= life-threatening; urgent intervention indicated; and grade 5= death related to AE.
Time frame: From first dose of study treatment (Day 1) through study completion
Number of Participants With TESAEs: Through Study Completion Date
TEAEs were defined as events that were new or worsened on or after receiving the first dose of study treatment and up through 30 days after the last dose of brentuximab vedotin or lenalidomide or 110 days after last dose of rituximab, whichever was later. An AE was classified as an SAE if it met one of the following criteria: fatal, life threatening, required or prolonged hospitalization, disabling/ incapacitating, congenital anomaly or birth defect, medically significant.
Time frame: From first dose of study treatment (Day 1) through study completion
OS in Cluster of Differentiation 30 (CD30)-Positive Participants
OS was defined as the time from the date of randomization to the date of death due to any cause. OS was evaluated in participants with CD30 expression status using a predefined cutoff of \>= 1%. Participants with CD30 tumor expression \>= 1% were classified as CD30-positive. CD30 positivity was defined as \>=1% of target lymphoid cells demonstrating membrane, cytoplasmic, and/or Golgi staining for CD30 at any intensity above background staining, as determined relative to the corresponding negative control. Participants who had not died were censored at the last known alive date or the data cutoff date, whichever was earlier.
Time frame: From the date of randomization until date of death or censoring date, whichever occurred first (maximum up to 50 months)
A total of 240 participants were enrolled in the study. Of these,10 participants were excluded as these participants were part of the Safety Run-In population prior to the random assignment stage of the trial, therefore they are excluded from the ITT population. Data for these 10 participants were not provided in any of the section of the result.
| Milestone | Brentuximab Vedotin + Lenalidomide + Rituximab | Placebo + Lenalidomide + Rituximab |
|---|---|---|
| Started | 112 | 118 |
| Intent-to-treat (itt) analysis set | 112 | 118 |
| Safety analysis set | 112 | 116 |
| Completed | 0 | 0 |
| Not completed | 112 | 118 |
| Withdrew: Withdrawal by subject | 7 | 11 |
| Withdrew: Death | 73 | 83 |
| Withdrew: Other | 32 | 24 |
OS was defined as the time from the date of randomization to the date of death due to any cause. Participants who had not died were censored at the last known alive date or the data cutoff date, whichever was earlier. OS was estimated using the Kaplan-Meier method.
| Months | Brentuximab Vedotin + Lenalidomide + Rituximab | Placebo + Lenalidomide + Rituximab |
|---|---|---|
| Overall Survival (OS) | 14.8 (10.3 to 21.5) | 7.8 (5.7 to 11.7) |
PFS was defined as the time from the date of randomization to the date of first documentation of progressive disease (PD) or to death due to any cause, whichever occurred first, based on the investigator assessment of tumor response according to the criteria defined by the Lugano Classification, 2014.
| Months | Brentuximab Vedotin + Lenalidomide + Rituximab | Placebo + Lenalidomide + Rituximab |
|---|---|---|
| Progression-Free Survival (PFS) as Assessed by Investigator Per Lugano 2014 | 4.2 (3.0 to 7.1) | 2.6 (1.4 to 3.1) |
ORR per Lugano 2014 by investigator was defined as the percentage of participants with a response assessment of complete response (CR) or partial response (PR) per the Lugano 2014 response criteria as assessed by the investigator.
| Percentage of participants | Brentuximab Vedotin + Lenalidomide + Rituximab | Placebo + Lenalidomide + Rituximab |
|---|---|---|
| Objective Response Rate (ORR) as Assessed by Investigator Per Lugano 2014 | 64.3 (54.7 to 73.1) | 41.5 (32.5 to 51.0) |
CR rate per Lugano 2014 by investigator was defined as the percentage of participants with a best response of CR per the Lugano 2014 response criteria as assessed by the investigator.
| Percentage of participants | Brentuximab Vedotin + Lenalidomide + Rituximab | Placebo + Lenalidomide + Rituximab |
|---|---|---|
| Complete Response (CR) Rate as Assessed by Investigator Per Lugano 2014 | 41.1 (31.9 to 50.8) | 18.6 (12.1 to 26.9) |
DOR was defined as the time from the first documentation of objective tumor response (CR or PR) to the first documentation of tumor progression per the Lugano 2014 response criteria, as assessed by the investigator, or death due to any cause, whichever occurred first.
| Months | Brentuximab Vedotin + Lenalidomide + Rituximab | Placebo + Lenalidomide + Rituximab |
|---|---|---|
| Duration of Response (DOR) as Assessed by Investigator Per Lugano 2014 | 8.3 (4.1 to 15.3) | 4.1 (2.8 to 8.1) |
An adverse event (AE) was any untoward medical occurrence in a clinical investigational participant administered a medicinal product and which did not necessarily have a causal relationship with this treatment. TEAEs were defined as events that were new or worsened on or after receiving the first dose of study treatment and up through 30 days after the last dose of brentuximab vedotin or lenalidomide or 110 days after last dose of rituximab, whichever was later. AEs included both serious AE (SAEs) and all other AEs. An AE was classified as an SAE if it met one of the following criteria: fatal, life threatening, required or prolonged hospitalization, disabling/ incapacitating, congenital anomaly or birth defect, medically significant.
| Participants | Brentuximab Vedotin + Lenalidomide + Rituximab | Placebo + Lenalidomide + Rituximab |
|---|---|---|
| Number of Participants With Treatment Emergent Adverse Events (TEAEs) | 109 | 113 |
An AE was any untoward medical occurrence in a clinical investigational participant administered a medicinal product and which did not necessarily have a causal relationship with this treatment. TEAEs were defined as events that were new or worsened on or after receiving the first dose of study treatment and up through 30 days after the last dose of brentuximab vedotin or lenalidomide or 110 days after last dose of rituximab, whichever was later. AE severity graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version (v) 5.0 where, grade 1=mild AE; grade 2=moderate AE; grade 3=severe AE; grade 4= life-threatening; urgent intervention indicated; and grade 5= death related to AE.
| Participants | Brentuximab Vedotin + Lenalidomide + Rituximab | Placebo + Lenalidomide + Rituximab |
|---|---|---|
| Grade 1 | 1 | 5 |
| Grade 2 | 9 | 17 |
| Grade 3 | 45 | 51 |
| Grade 4 | 38 | 31 |
| Grade 5 | 16 | 9 |
TEAEs were defined as events that were new or worsened on or after receiving the first dose of study treatment and up through 30 days after the last dose of brentuximab vedotin or lenalidomide or 110 days after last dose of rituximab, whichever was later. An AE was classified as an SAE if it met one of the following criteria: fatal, life threatening, required or prolonged hospitalization, disabling/ incapacitating, congenital anomaly or birth defect, medically significant.
| Participants | Brentuximab Vedotin + Lenalidomide + Rituximab | Placebo + Lenalidomide + Rituximab |
|---|---|---|
| Number of Participants With Treatment Emergent Serious Adverse Events (TESAEs) | 73 | 59 |
An AE was any untoward medical occurrence in a clinical investigational participant administered a medicinal product and which did not necessarily had a causal relationship with this treatment. TEAEs were defined as events that were new or worsened on or after receiving the first dose of study treatment and up through 30 days after the last dose of brentuximab vedotin or lenalidomide or 110 days after last dose of rituximab, whichever was later. AEs included both SAEs and all other AEs.
Results for this outcome have not been posted.
An AE was any untoward medical occurrence in a clinical investigational participant administered a medicinal product and which did not necessarily had a causal relationship with this treatment. TEAEs were defined as events that were new or worsened on or after receiving the first dose of study treatment and up through 30 days after the last dose of brentuximab vedotin or lenalidomide or 110 days after last dose of rituximab, whichever was later. AE severity graded using the NCI-CTCAE v 5.0 where, grade 1=mild AE; grade 2=moderate AE; grade 3=severe AE; grade 4= life-threatening; urgent intervention indicated; and grade 5= death related to AE.
Results for this outcome have not been posted.
TEAEs were defined as events that were new or worsened on or after receiving the first dose of study treatment and up through 30 days after the last dose of brentuximab vedotin or lenalidomide or 110 days after last dose of rituximab, whichever was later. An AE was classified as an SAE if it met one of the following criteria: fatal, life threatening, required or prolonged hospitalization, disabling/ incapacitating, congenital anomaly or birth defect, medically significant.
Results for this outcome have not been posted.
OS was defined as the time from the date of randomization to the date of death due to any cause. OS was evaluated in participants with CD30 expression status using a predefined cutoff of \>= 1%. Participants with CD30 tumor expression \>= 1% were classified as CD30-positive. CD30 positivity was defined as \>=1% of target lymphoid cells demonstrating membrane, cytoplasmic, and/or Golgi staining for CD30 at any intensity above background staining, as determined relative to the corresponding negative control. Participants who had not died were censored at the last known alive date or the data cutoff date, whichever was earlier.
| Months | Brentuximab Vedotin + Lenalidomide + Rituximab | Placebo + Lenalidomide + Rituximab |
|---|---|---|
| OS in Cluster of Differentiation 30 (CD30)-Positive Participants | 14.2 (7.1 to 39.4) | 8.8 (6.0 to 24.4) |
Collected over SAEs and other AEs: From first dose of study treatment (Day 1) up to 30 days after last dose of brentuximab vedotin or lenalidomide or 110 days after last dose of rituximab, whichever was later (maximum up to 50 months)'. All cause mortality: From the date of randomization until date of death or censoring date, whichever occurred first (maximum up to 50 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Brentuximab Vedotin + Lenalidomide + Rituximab | 78/112 (69.6%) | 73/112 (65.2%) | 105/112 (93.8%) |
| Placebo + Lenalidomide + Rituximab | 92/118 (78%) | 59/116 (50.9%) | 101/116 (87.1%) |
| Event | Brentuximab Vedotin + Lenalidomide + Rituximab | Placebo + Lenalidomide + Rituximab |
|---|---|---|
| PneumoniaInfections and infestations | 14/112 | 8/116 |
| COVID-19Infections and infestations | 9/112 | 6/116 |
| COVID-19 pneumoniaInfections and infestations | 8/112 | 5/116 |
| Febrile neutropeniaBlood and lymphatic system disorders | 7/112 | 7/116 |
| General physical health deteriorationGeneral disorders | 5/112 | 3/116 |
| PyrexiaGeneral disorders | 3/112 | 5/116 |
| Septic shockInfections and infestations | 4/112 | 1/116 |
| Urinary tract infectionInfections and infestations | 4/112 | 0/116 |
| Acute kidney injuryRenal and urinary disorders | 2/112 | 4/116 |
| ThrombocytopeniaBlood and lymphatic system disorders | 3/112 | 1/116 |
| Event | Brentuximab Vedotin + Lenalidomide + Rituximab | Placebo + Lenalidomide + Rituximab |
|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 53/112 | 39/116 |
| ThrombocytopeniaBlood and lymphatic system disorders | 39/112 | 28/116 |
| DiarrhoeaGastrointestinal disorders | 37/112 | 29/116 |
| AnaemiaBlood and lymphatic system disorders | 35/112 | 33/116 |
| FatigueGeneral disorders | 28/112 | 21/116 |
| AstheniaGeneral disorders | 25/112 | 16/116 |
| Peripheral sensory neuropathyNervous system disorders | 24/112 | 9/116 |
| ConstipationGastrointestinal disorders | 21/112 | 23/116 |
| PyrexiaGeneral disorders | 21/112 | 14/116 |
| COVID-19Infections and infestations | 21/112 | 15/116 |
| Age, Continuous(Years) | Brentuximab Vedotin + Lenalidomide + Rituximab | Placebo + Lenalidomide + Rituximab | Total |
|---|---|---|---|
| Mean | 69.2 ± 12.7 | 65.8 ± 14.5 | 67.4 ± 13.8 |
| Sex: Female, Male(Participants) | Brentuximab Vedotin + Lenalidomide + Rituximab | Placebo + Lenalidomide + Rituximab | Total |
|---|---|---|---|
| Female | 52 | 48 | 100 |
| Male | 60 | 70 | 130 |
| Race/Ethnicity, Customized(Participants) | Brentuximab Vedotin + Lenalidomide + Rituximab | Placebo + Lenalidomide + Rituximab | Total |
|---|---|---|---|
| Ethnicity — Hispanic, Latino/a, or of Spanish Origin | 4 | 5 | 9 |
| Ethnicity — Not of Hispanic, Latino/a, or Spanish Origin | 90 | 84 | 174 |
| Ethnicity — Unknown | 0 | 1 | 1 |
| Ethnicity — Not Reportable | 18 | 28 | 46 |
| Race/Ethnicity, Customized(Participants) | Brentuximab Vedotin + Lenalidomide + Rituximab | Placebo + Lenalidomide + Rituximab | Total |
|---|---|---|---|
| Race — American Indian or Alaska Native | 0 | 1 | 1 |
| Race — Asian | 28 | 32 | 60 |
| Race — White | 65 | 56 | 121 |
| Race — Other | 0 | 1 | 1 |
| Race — Unknown | 1 | 0 | 1 |
| Race — Not Reported | 18 | 28 | 46 |
Showing the first 100 of 143 sites across 14 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Aug 2020 to primary completion in Jan 2026, 65 months.
Results were first posted in Oct 2026, 8 months after primary completion.
Of 37 industry-sponsored phase 3 interventional studies under Lymphoma, Large B-Cell, Diffuse, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 82. This study's 65 months is above that.
Counting every sponsor, half of 73 studies reached it within 57 months; a quarter within 39 and three quarters within 99.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Brentuximab Vedotin
Lymphoma, Large B-Cell, Diffuse →
Seagen, a wholly owned subsidiary of Pfizer →